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ABSTRACT  
Severe treatment-induced toxicities can have clinical consequences such as hospitalization 
or treatment modifications, which in its turn may deteriorate prognosis of cancer patients. 
Identification of determinants of treatment-induced toxicities is essential to develop 
strategies that promote therapy compliance and enhance quality of life. Whereas toxicities 
are systematically recorded and graded per protocol in most clinical trials, observational 
studies often depend on retrospective data collection from medical records collected as 
standard care. Existing population-based or patient cohorts are a valuable source of 
information, even when relying on retrospective data collection, but comparisons across 
studies are hampered by lack of a uniform definition for toxicity outcomes. We propose a 
new standardized approach to summarize toxicities in observational studies that rely on 
medical records for outcome assessment. We recommend the term “toxicity-induced 
modification of treatment” (TIMT) to cover all toxicities that are responsible for changes in 
a planned treatment schedule. We define a TIMT as either: i) a dose reduction, ii) 
temporary interruption, iii) discontinuation of therapy, or iv) an unanticipated switch to 
another regimen, as a result of treatment-induced toxicities and not due to progressive 
disease. This definition will provide clinically relevant information, especially when data on 
specific adverse events and Common Terminology Criteria for Adverse Events (CTCAE) 
grades are not uniformly available. Implementation of this definition empowers 
comparisons across studies, facilitates communication between clinicians and researchers 
and will allow new research questions in this active field of research.  
 
Keywords: toxicity, definition, treatment modification, body composition, determinants, 
cancer  
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CURRENT PERSPECTIVES 
 
“Two monologues do not make a dialogue.” – Jeff Daly. The importance of successful 
communication is explicitly recognized in clinical and scientific fields, especially when 
working at the interface of disciplines (1). Talking the same language, or at least 
understanding each other languages, facilitates efficient communication. One particular 
field of research where we increasingly recognize confusion and lack of uniform definitions 
for study outcomes, is related to identification of determinants of treatment-induced 
toxicities in cancer patients.  
Most systemic cancer treatments come at the expense of adverse events. Severe, 
acute toxicities inevitably have clinical consequences such as hospitalization or modification 
of the treatment schedule, which in its turn may deteriorate prognosis (2, 3). Moreover, 
some toxicities can persist far beyond active treatment and can impact, to a greater or 
lesser extent, quality of life and the ability to function of cancer patients (4, 5).  
Assessment of toxicity profiles is an important aspect of clinical trials initiated for 
the evaluation of new anticancer drugs. The widely adopted Common Terminology Criteria 
for Adverse Events (CTCAE), developed by the US National Cancer Institute, are often used 
for identification and characterization of toxicities. Clinical phase I studies aim to identify 
the maximum tolerated dose (MTD) or the recommended phase II dose (RPTD) of the 
agent or regimen under study and commonly apply the CTCAE classification. In these dose 
escalation studies, the dose-limiting toxicities (DLTs) determine at which dose a drug is 
not tolerable and safe anymore. The adverse events determining the DLT are often defined 
as CTCAE grade 3–5 toxicities during cycle 1 (6) or the first 21 or 28 days of treatment 
and are prospectively scored, although definitions are extremely heterogeneous (7) and 
may depend on the schedule and type of drug (e.g. traditional chemotherapeutic versus 
molecular targeted agents) (8). Although primarily developed for clinical cancer trials, 
CTCAE criteria are also commonly applied in routine clinical care to evaluate treatment-
induced toxicities in cancer patients undergoing treatment.   
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Determinants of treatment-induced toxicities in cancer patients 
So far, management of acute toxicities largely depends on supportive 
pharmacotherapeutic approaches, including for example antiemetics, colony-stimulating 
factors, antibiotics and anti-motility agents for diarrhea. These drugs have been proven to 
efficiently treat a variety of acute adverse events, however, for various other toxicities no 
clear consensus about efficient management has been reached, yet (9, 10). One particular 
example is acute severe chemotherapy-induced peripheral neuropathy, which cannot be 
effectively treated and is therefore a major reason for dose reduction or premature 
discontinuation of chemotherapy. Exact causes and predictors of toxicities are largely 
unknown and variations in toxicity profiles between patients seem to be driven by clinical, 
genetic, physiological as well as nutritional and other lifestyle factors (11).  
Evidence is accumulating that nutrition and lifestyle are associated with risk of 
toxicities during and after systemic cancer therapy. Knowledge in this emerging field of 
research is fueled by advanced technologies that allow integration and efficient use of 
routinely collected clinical data. The role of body composition, assessed through clinically 
available computed tomography (CT) scans, is perhaps the most powerful example of 
efficient use of clinical data (12). A lower lean mass and sarcopenia or sarcopenic obesity, 
referring to depletion of skeletal muscle mass with or without loss of fat mass, have been 
associated with an increased risk of toxicities in a variety of studies among cancer patients 
receiving chemotherapy, molecular targeted therapy, and immunotherapy (13). The 
consistency of these findings highlights the relevance and urgency of this promising area 
of research, and has also resulted in growing interest in other nutritional or lifestyle factors 
as determinants of treatment-induced toxicities (14, 15).  
New avenues for potential nutritional or lifestyle interventions that can help to 
mitigate treatment-induced toxicities will come from observational studies. Given the 
wealth of information available through existing population-based or patient cohorts, 
various modifiable nutrition and lifestyle exposures can be studied in relation to risk of 
toxicities in cancer patients. To date, body composition is again the most striking example 
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showing the elegance of efficient use of data from patient cohorts. However, also other 
exposures are increasingly being explored. For example, the association between 
circulating levels of folate and related biomarkers in patients receiving cytotoxic anti-folate 
therapies, such as methotrexate or 5-fluorouracil, got attention (16). The recent advances 
in medical oncology, and particularly the introduction of molecular targeted agents and 
immunotherapy, even provide novel possibilities to further explore and expand this 
emerging and active field of research.  
Lack of a uniform definition for toxicity in observational studies 
Currently, a uniform and feasible definition for toxicity outcomes in observational studies 
is lacking and different criteria have been used across different studies, which raises the 
question whether we all speak the same language in this context. Ideally, occurrence and 
severity of toxicities are prospectively scored in a systematic way by using well-defined 
criteria, such as the CTCAE classification. Functional, clinical or laboratory tests can 
complement these grading systems with relevant information regarding specific treatment-
related symptoms. Also, patient-reported outcomes assessed through validated 
questionnaires or digital applications are increasingly considered of crucial importance and 
should be recognized as such in clinical care as well as research dedicated to toxicity 
outcomes (17, 18).  
As described above, especially in studies with treatment efficiency and safety 
profiles as primary outcomes, such as phase I-IV clinical trials, detailed data on CTCAE 
grades or patient-reported outcomes are commonly available. However, in these clinical 
trials comprehensive data on nutritional and lifestyle factors are usually not collected. 
Detailed exposure data, such as food frequency questionnaires, physical activity measures, 
other lifestyle characteristics or body composition data, are available in various large-scale 
cohort studies (e.g. (19-21)). These studies mainly rely on retrospective review of medical 
records. In most clinical centers standardized collection of toxicity data by using CTCAE 
criteria is not part of routine clinical care, leading to variation in registration of toxicities 
within and between centers. 
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This inconsistency can be nicely illustrated by the aforementioned studies focusing 
on body composition in relation to toxicities, as these studies cover various types of cancer, 
different treatment strategies and it comprises a substantial number of studies. As can be 
seen in Table 1, many studies conducted so far also used the term DLT to collectively 
describe any treatment modifications, with or without consideration of severe adverse 
events (CTCAE grade ≥3). In these instances, treatment modifications commonly refer to 
a temporary interruption (delay), dose reduction or permanent discontinuation of therapy 
due to adverse effects. It should be noted that use of the term DLT or equivalents is not 
limited to studies focusing on body composition, but has also been applied in relation to 
other exposures such as nutritional status and resting energy expenditure (22, 23). 
In our opinion, the term DLT is confusing in this context as treatment modifications 
do not necessarily refer to the concept of DLTs as classically used in medical oncology. In 
contrast to the clinical phase I dose escalation studies, most studies focusing on nutritional 
and lifestyle determinants of toxicity in population-based or patient cohorts are not 
primarily designed or meant to study increasing doses of drugs in subsequent groups of 
patients. Instead, associations between the exposures of interest and toxicities in a 
representative group of patients receiving standard care will provide relevant information 
on determinants of toxicities. Use of the term DLT outside the scope of clinical phase I-IV 
trials is therefore causing confusion, especially since heterogeneous definitions are used 
across different studies. 
Toxicity-induced modification of treatment (TIMT): a new and uniform definition 
Given the controversies about the term DLT used in observational studies, we propose a 
new definition to collectively summarize toxicities in studies that rely on retrospective 
review of medical records for outcome assessment. We recommend to use the term 
toxicity-induced modification of treatment (TIMT) to cover any toxicity that is responsible 
for changes in the treatment schedule. This definition will provide clinically relevant 
information, especially when data on specific adverse events and CTCAE grades are not 
uniformly available. As part of the TIMT definition, we recommend inclusion of the 
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previously mentioned treatment modifications, i.e. a reduction of the dose, a delay, or a 
premature discontinuation of the therapy (Table 2). Furthermore, we propose to add an 
unanticipated switch in regimes as one of the criteria for a TIMT. Switching from one regime 
to another is usually a consequence of limited tolerance and experienced toxicities in the 
patients. One particular example is the common switch from CAPOX to capecitabine 
monotherapy in case of severe neurotoxicity (24). Naturally, switches that are planned, 
such as the sequential regimes or combinations with non-cytotoxic drugs, are not 
considered as TIMT. Also modifications not resulting from toxicities, such as requested 
interruptions because of holidays or other personal circumstances, should not be 
considered as a TIMT. Ideally, TIMTs should be evaluated during the entire phase of active 
treatment, and monitoring of time (in days or cycles) to occurrence of the first TIMT can 
provide additional information. For studies evaluating determinants of toxicities of modern 
classes of anticancer drugs, such as targeted agents that are administered for a prolonged 
time, or checkpoint-inhibitors for which specific immune-related adverse events can be 
expected, the TIMT definition is also suitable as a primary outcome, whilst additional 
criteria may be used based on the specific research questions addressed. 
Concluding remarks and perspectives 
To facilitate research on potential determinants of treatment-induced toxicity in cancer 
patients, we propose the term toxicity-induced modification of treatment (TIMT) to define 
outcomes in observational studies within population-based or patients cohorts. Especially 
studies that rely on retrospective data collection from medical records as part of standard 
care may benefit from this uniform definition that also favors comparisons between studies. 
In our opinion, one of the strengths of the TIMT definition is that clinical consequences (i.e. 
modifications of treatment) are considered independent of the (CTCAE) grade of toxicities. 
One limitation of the grading systems for symptom severity is that low-grade chronic 
toxicities are often neglected, whilst these toxicities may seriously impact quality of life of 
the patient, especially in the context of modern treatment strategies that are administered 
continuously and for a prolonged time (25). Indeed, low-grade toxicities can result in 
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substantial treatment modifications especially in patients receiving targeted therapy (26), 
whereas patients with high-grade toxicities may be able to complete or continue therapy 
(27), indicating that grades of toxicities are not linked to clinical consequences at all times. 
This pattern is also inherent to individual tolerance of toxicities and perception by patients 
as well as physicians (28). In view of this, the TIMT definition is different from the CTCAE 
criteria as it solitarily focuses on toxicities with clinical consequences, and hence may have 
important implications for prognosis of the patient (2, 3). Naturally, adequate and essential 
data on specific adverse events and their severity, either physician- or patient-reported, 
can provide complementary information in these type of studies whenever available.    
Given the existence of various well-described patient cohorts with valuable 
information on nutrition, lifestyle and other modifiable factors, future studies may expand 
their view and benefit from clinically available data by studying the association between 
various exposures and TIMT. As the TIMT definition can be easily applied in heterogeneous 
patient populations receiving standard care across different centers, also patients with rare 
cancers can and should be considered in future studies. Needless to say is that the 
advances in medical oncology, including introduction of molecular targeted therapy and 
immunotherapy, provide even more exciting opportunities for this research field. 
Exposures that warrant further attention include, but are not limited to smoking, energy 
intake, protein intake, alcohol consumption, biomarkers of dietary intake (e.g. folate, 
vitamin D) and inflammation (e.g. cytokines), dietary supplements and physical activity. 
In this context and by using clinically available data, one can even look beyond the 
traditional exposures and explore other fascinating areas such as microbiota composition 
(29), genetic variants (30) and metabolites (31) in relation to toxicity-induced modification 
of treatment. That’s in a name! 
  
  
9 
 
Acknowledgements 
Views and opinions of the authors are supported by discussions with experts in the field 
and preliminary work of undergraduate and graduate students. Specifically, we would like 
to thank Anne Geijsen, Jip van den Berg, Liesbeth Posthuma and Lena Fricke for their input 
in the scientific discussions. As this perspective is not intended as a comprehensive review 
of literature and the space for references is limited, we did not describe all studies 
presenting results on determinants of toxicities in cancer patients. However, we recognize 
and acknowledge all authors contributing to knowledge and work in this field.  
Funding 
This research did not receive any specific grant from funding agencies in the public, 
commercial, or not-for-profit sectors. 
Conflict of interest statement  
None declared. 
REFERENCES 
1. Potter JD. At the interfaces of epidemiology, genetics and genomics. Nat Rev Genet 
2001;2(2):142-7. 
2. Morris M, Platell C, Fritschi L, Iacopetta B. Failure to complete adjuvant chemotherapy is 
associated with adverse survival in stage III colon cancer patients. Br J Cancer 2007;96(5):701-7. 
3. Budman DR, Berry DA, Cirrincione CT, Henderson IC, Wood WC, Weiss RB, et al. Dose and 
Dose Intensity as Determinants of Outcome in the Adjuvant Treatment of Breast Cancer. JNCI: 
Journal of the National Cancer Institute 1998;90(16):1205-1211. 
4. Mols F, Beijers T, Lemmens V, Hurk CJvd, Vreugdenhil G, Poll-Franse LVvd. Chemotherapy-
Induced Neuropathy and Its Association With Quality of Life Among 2- to 11-Year Colorectal Cancer 
Survivors: Results From the Population-Based PROFILES Registry. Journal of Clinical Oncology 
2013;31(21):2699-2707. 
5. Schmielau J, Rick O, Reuss-Borst M, Kalusche-Bontemps EM, Steimann M. Rehabilitation of 
Cancer Survivors with Long-Term Toxicities. Oncology Research and Treatment 2017;40(12):764-
771. 
  
10 
 
6. Postel-Vinay S, Collette L, Paoletti X, Rizzo E, Massard C, Olmos D, et al. Towards new 
methods for the determination of dose limiting toxicities and the assessment of the recommended 
dose for further studies of molecularly targeted agents – Dose-Limiting Toxicity and Toxicity 
Assessment Recommendation Group for Early Trials of Targeted therapies, an European Organisation 
for Research and Treatment of Cancer-led study. European Journal of Cancer 2014;50(12):2040-
2049. 
7. Le Tourneau C, Razak ARA, Gan HK, Pop S, Diéras V, Tresca P, et al. Heterogeneity in the 
definition of dose-limiting toxicity in phase I cancer clinical trials of molecularly targeted agents: A 
review of the literature. European Journal of Cancer 2011;47(10):1468-1475. 
8. Eisenhauer EA, O’Dwyer PJ, Christian M, Humphrey JS. Phase I Clinical Trial Design in Cancer 
Drug Development. Journal of Clinical Oncology 2000;18(3):684-684. 
9. Cinausero M, Aprile G, Ermacora P, Basile D, Vitale MG, Fanotto V, et al. New Frontiers in the 
Pathobiology and Treatment of Cancer Regimen-Related Mucosal Injury. Frontiers in Pharmacology 
2017;8:354. 
10. Lotfi-Jam K, Carey M, Jefford M, Schofield P, Charleson C, Aranda S. Nonpharmacologic 
strategies for managing common chemotherapy adverse effects: a systematic review. J Clin Oncol 
2008;26(34):5618-29. 
11. Tejpar S, Yan P, Piessevaux H, Dietrich D, Brauchli P, Klingbiel D, et al. Clinical and 
pharmacogenetic determinants of 5-fluorouracyl/leucovorin/irinotecan toxicity: Results of the 
PETACC-3 trial. Eur J Cancer 2018;99:66-77. 
12. Mourtzakis M, Prado CM, Lieffers JR, Reiman T, McCargar LJ, Baracos VE. A practical and 
precise approach to quantification of body composition in cancer patients using computed 
tomography images acquired during routine care. Appl Physiol Nutr Metab 2008;33(5):997-1006. 
13. Kazemi-Bajestani SMR, Mazurak VC, Baracos V. Computed tomography-defined muscle and 
fat wasting are associated with cancer clinical outcomes. Seminars in Cell & Developmental Biology 
2016;54(Supplement C):2-10. 
14. O’Flanagan CH, Smith LA, McDonell SB, Hursting SD. When less may be more: calorie 
restriction and response to cancer therapy. BMC Medicine 2017;15:106. 
15. Wedlake L, Shaw C, McNair H, Lalji A, Mohammed K, Klopper T, et al. Randomized controlled 
trial of dietary fiber for the prevention of radiation-induced gastrointestinal toxicity during pelvic 
radiotherapy. Am J Clin Nutr 2017;106(3):849-857. 
  
11 
 
16. Yan M, Ho C, Winquist E, Jonker D, Rayson D, Stitt L, et al. Pretreatment Serum Folate Levels 
and Toxicity/Efficacy in Colorectal Cancer Patients Treated With 5-Fluorouracil and Folinic Acid. Clin 
Colorectal Cancer 2016;15(4):369-376.e3. 
17. Snyder CF, Aaronson NK, Choucair AK, Elliott TE, Greenhalgh J, Halyard MY, et al. 
Implementing patient-reported outcomes assessment in clinical practice: a review of the options and 
considerations. Quality of Life Research 2012;21(8):1305-1314. 
18. Basch E, Dueck AC, Rogak LJ, Minasian LM, Kelly WK, O'Mara AM, et al. Feasibility 
Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials. 
JAMA Oncol 2017;3(8):1043-1050. 
19. Winkels RM, Heine-Broring RC, van Zutphen M, van Harten-Gerritsen S, Kok DE, van 
Duijnhoven FJ, et al. The COLON study: Colorectal cancer: Longitudinal, Observational study on 
Nutritional and lifestyle factors that may influence colorectal tumour recurrence, survival and quality 
of life. BMC Cancer 2014;14:374. 
20. Kwan ML, Ambrosone CB, Lee MM, Barlow J, Krathwohl SE, Ergas IJ, et al. The Pathways 
Study: a prospective study of breast cancer survivorship within Kaiser Permanente Northern 
California. Cancer Causes Control 2008;19(10):1065-76. 
21. Bueno-de-Mesquita HB, Gonzalez CA. Main hypotheses on diet and cancer investigated in the 
EPIC Study. European Prospective Investigation into Cancer and Nutrition. Eur J Cancer Prev 
1997;6(2):107-17. 
22. Jouinot A, Vazeille C, Durand JP, Huillard O, Boudou-Rouquette P, Coriat R, et al. Resting 
energy expenditure in the risk assessment of anticancer treatments. Clin Nutr 2017. 
23. Arrieta O, De la Torre-Vallejo M, Lopez-Macias D, Orta D, Turcott J, Macedo-Perez EO, et al. 
Nutritional Status, Body Surface, and Low Lean Body Mass/Body Mass Index Are Related to Dose 
Reduction and Severe Gastrointestinal Toxicity Induced by Afatinib in Patients With Non-Small Cell 
Lung Cancer. Oncologist 2015;20(8):967-74. 
24. Banach M, Juranek JK, Zygulska AL. Chemotherapy‐induced neuropathies—a growing 
problem for patients and health care providers. Brain and Behavior 2017;7(1):e00558. 
25. Seruga B, Templeton AJ, Badillo FEV, Ocana A, Amir E, Tannock IF. Under-reporting of harm 
in clinical trials. The Lancet Oncology 2016;17(5):e209-e219. 
26. Castellanos EH, Chen SC, Drexler H, Horn L. Making the Grade: The Impact of Low-Grade 
Toxicities on Patient Preference for Treatment With Novel Agents. J Natl Compr Canc Netw 
2015;13(12):1490-5. 
  
12 
 
27. Ewer MS, Suter TM, Lenihan DJ, Niculescu L, Breazna A, Demetri GD, et al. Cardiovascular 
events among 1090 cancer patients treated with sunitinib, interferon, or placebo: A comprehensive 
adjudicated database analysis demonstrating clinically meaningful reversibility of cardiac events. 
European Journal of Cancer 2014;50(12):2162-2170. 
28. Bayo J, Prieto B, Rivera F. Comparison of Doctors' and Breast Cancer Patients' Perceptions 
of Docetaxel, Epirubicin, and Cyclophosphamide (TEC) Toxicity. Breast J 2016;22(3):293-302. 
29. Roy S, Trinchieri G. Microbiota: a key orchestrator of cancer therapy. Nat Rev Cancer 
2017;17(5):271-285. 
30. Giacomini KM, Yee SW, Mushiroda T, Weinshilboum RM, Ratain MJ, Kubo M. Genome-wide 
association studies of drug response and toxicity: an opportunity for genome medicine. Nat Rev Drug 
Discov 2017;16(1):1. 
31. Rattner J, Bathe OF. Monitoring for Response to Antineoplastic Drugs: The Potential of a 
Metabolomic Approach. Metabolites 2017;7(4). 
  
13 
 
Table 1: An overview of studies describing the association between body composition and treatment-induced toxicities 
Studya  PMID Toxicity outcome 
(definition) 
Criteria Type of cancer No of 
patients 
Treatment 
Mir, 2012 22666367 DLT any toxicities leading to a dose reduction, temporary or permanent 
discontinuation of therapy 
advanced hepatocellular 
carcinoma 
n=40 targeted therapy 
(sorafenib) 
Huillard, 2013 23462722 early DLT any toxicity leading to dose reduction, temporary or permanent 
discontinuation in the first cycle (i.e. 6 weeks) 
metastatic renal cell cancer n=61 targeted therapy 
(sunitinib) 
Tan, 2015 25498359 DLT toxicity leading to postponement of treatment, a drug dose 
reduction or definitive interruption of drug administration 
locally advanced esophago-
gastric cancer 
n=89 neoadjuvant 
chemotherapy 
Ali, 2016 
 
26814378 DLT dose reductions or termination of therapy in the first 4 cycles colorectal cancer n=80 chemotherapy 
(FOLFOX) 
Cushen, 2016 28531567 DLT any grade ≥ 3 toxicity leading to dose reduction, temporary or 
permanent discontinuation of therapy 
metastatic castrate resistant 
prostate cancer 
n=63 chemotherapy 
(docetaxel) 
Cespedes 
Feliciano, 2017 
28881381 1. early discontinuation  
2. treatment delay 
3. dose reduction 
1. < 6 cycles or switch to another regimen 
2. ≥ 3 days later than recommendations from guideline 
3. relative dose intensity (RDI) < 0.70 
stage II – III colon cancer n=533 chemotherapy 
(FOLFOX) 
Shachar, 2017 28143874 treatment-related 
toxicity 
any and specific grade 3-4 toxicities or dose reductions, treatment 
delays and hospitalizations  
stage I-III breast cancer n=151 chemotherapy 
(taxane-based) 
Shachar, 2017 27489287 “any adverse event”  hospitalization, grade 3–4 toxicity, dose reductions, or dose delay metastatic breast cancer n=40 chemotherapy 
(taxane-based) 
Palmela, 2017 28337365 DLT any grade 3 or 4 toxicity associated with physician-ordered dose 
reduction or termination of therapy. 
locally advanced gastric 
cancer 
n=48 neoadjuvant 
chemotherapy 
Murimwa, 2017 29184684 acute toxicity grade ≥3 toxicity within 3 months of radiotherapy locally advanced esophageal 
cancer 
n=56 chemoradiation 
Wendrich, 2017 28688687 CDLT any toxicity resulting in dose-reduction of ≥50%, postponement of 
≥4 days or a definite termination of chemotherapy after the first or 
second cycle of therapy 
locally advanced head and 
neck squamous cell 
carcinoma 
n=112 radiochemotherapy 
Cushen, 2017 24685884 DLT any toxicity leading to dose reduction, temporary or permanent 
discontinuation of therapy. Primary analysis compares rates of 
grade 3-4 toxicity, dose delays, dose reductions, and combinations 
as DLT 
metastatic renal cell 
carcinoma 
n=55 targeted therapy 
(sunitinib) 
Daly, 2017 28072766 DLT and high-grade (3-
4) adverse events 
any dose delays or early cessation of treatment as a result of 
significant toxicity (grades 3–4) during 4 cycles  
metastatic melanoma n=84 immunotherapy 
(ipilimumab) 
a This table present various studies focusing on body composition and toxicity outcomes to highlight the heterogeneity in definitions for toxicity, but does not provide a 
comprehensive literature review. Only studies with retrospective data collection from medical records are presented. These studies are acknowledged and referenced by 
their PubMed identifier (PMID). Studies based on clinical trials or data collection per protocol are not included in this table. Body composition includes measures of muscle 
(area / mass / index / gauge), fat (area / mass), intramuscular fat and sarcopenia or sarcopenic obesity in these studies. Abbreviations: CDLT; chemotherapy dose-limiting 
toxicity, DLT; dose-limiting toxicity, FOLFOX; chemotherapeutic regimen containing leucovorin, 5-fluorouracil and oxaliplatin, RDI; relative dose intensity.
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Table 2: Proposed definition and criteria for toxicity outcomes in observational studies 
Proposed term Toxicity-induced modification of treatment (TIMT) 
Including - Dose reduction 
- Interruption / delay of therapy 
- Discontinuation of therapy 
- Switch to an alternative regimena 
Excludingb - Discontinuation of therapy because of progressive disease 
- Interruption / delay of therapy because of non-clinical reasonsc  
- Switch to another regimen per protocol (e.g. sequential regimens) 
a referring to an unanticipated switch to another regimen which is resulting from severe 
toxicities experienced by the patient. b these events should not be scored as a toxicity-
induced modification of treatment (TIMT). c reasons not primarily related to treatment 
e.g. holiday / birthday.  
 
 
